Overexpression of the KIT/SCF in Uveal Melanoma Does Not Translate Into Clinical Efficacy of Imatinib Mesylate

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-2243
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Rare KIT (CD117) Expression in Multiple Myeloma Abrogates the Usefulness of Imatinib Mesylate Treatment

Virchows Archiv
MedicineForensic MedicinePathologyCell BiologyMolecular Biology
2004English

Does Ocular Treatment of Uveal Melanoma Influence Survival?

British Journal of Cancer
Cancer ResearchOncology
2010English

[Corrigendum] Antiproliferative Effects of Imatinib Mesylate on ZR‑75‑1 and MDA‑MB‑231�cell Lines via PDGFR‑β, PDGF‑BB, C‑Kit and SCF Expression

International Journal of Molecular Medicine
MedicineGenetics
2019English

Emerging Insights Into the Molecular Pathogenesis of Uveal Melanoma

Future Oncology
MedicineCancer ResearchOncology
2008English

Phase I Clinical Trial Combining Imatinib Mesylate and IL-2

OncoImmunology
OncologyAllergyImmunology
2013English

Clinical Significance of Immunohistochemistry for Detection of BAP1 Mutations in Uveal Melanoma

Modern Pathology
Forensic MedicinePathology
2014English

Immunoexpression of Macroh2a in Uveal Melanoma

Applied Sciences (Switzerland)
InstrumentationMaterials ScienceFluid FlowEngineeringComputer Science ApplicationsProcess ChemistryTransfer ProcessesTechnology
2019English

Prognosis in Uveal Melanoma

British Journal of Ophthalmology
Molecular NeuroscienceOphthalmologySensory SystemsCellular
1948English

Does Complete Renal Denervation Translate Into Superior Clinical Outcomes? Lessons Learned From Denervation of Accessory Renal Arteries

Clinical Research in Cardiology
MedicineCardiovascular MedicineCardiology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy